Clinical trials: Crohn's
Inflammatory Bowel Diseases, Crohn Disease
Intestinal Ultrasound Guided Management in Inflammatory Bowel Disease
This randomized controlled trial evaluates whether adding point-of-care intestinal ultrasound (IUS) to standard of care changes clinical management in patients with inflammatory bowel disease (IBD).
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Colitis, Ulcerative
- Trial name
- NCT07775352
- Testing
- Intestinal ultrasound (IUS), Standard of care
- Where
- Thailand
- Volunteers
- 137 people
- Sponsor
- Mahidol University
Crohn's Disease
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
Background: Crohn s disease (CD) is an inflammatory bowel disease. It causes inflammation of the gut. Symptoms may include diarrhea, abdominal pain, fatigue, weight loss and malnutrition.
- Trial name
- NCT03167437
- Testing
- Vorinostat, Ustekinumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Crohn Disease
An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients With Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation Study
The aim of the study is to assess the long-term efficacy and safety of a ustekinumab 90mg subcutaneous (SC) every 4 weeks (Q4w) regimen in patients with Crohn's disease previously enrolled in the REScUE study (NCT04245215)…
- Trial name
- REScUE-OLE (NCT05299931)
- Testing
- Ustekinumab
- Where
- Belgium
- Volunteers
- 41 people
- Sponsor
- Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW
Crohn's Disease
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
This is a phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate to severe Crohn's Disease (CD).
- Trial name
- SPECIFI-CD (NCT06637631)
- Testing
- SAR441566
- Where
- 141 sites in United States, Argentina and 22 more
- Volunteers
- 105 people
- Sponsor
- Sanofi
Crohn's Disease
Impact of Diet and Lifestyle Modification on the Intestinal Barrier Integrity in Crohn's Disease
The goal of this prospective interventional study is to evaluate whether the targeted avoidance of a particular food that was diagnosed to be disruptive for the intestinal barrier during confocal laser endomicroscopy (CLE)…
- Trial name
- LeakyDiet (NCT06719778)
- Testing
- Two-stage nutritional therapy concept
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Universität Duisburg-Essen
Crohn Disease (CD), Crohn Disease
Cranberry and Gut Health in Crohn's Disease
This study is investigating whether a cranberry-based dietary supplement, rich in polyphenols and fiber, can enhance gut health in individuals with Crohn's disease.
- Trial name
- NCT07170462
- Testing
- Cranberry powder
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Ana Maldonado-Contreras
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC)
Prospective Evaluation of Flare Detection in IBD With Digital Biomarkers: Bring Your Own Device Study
The aim of this study is to identify HRV changes predictive of IBD flares using patient-own wearable devices in a large cohort supplemented by additional data layers including sleep parameters, step count and clinical data…
- Conditions
- Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn Disease (CD)
- Trial name
- BYOD (NCT07647640)
- Testing
- Wearing their own wearable device.
- Where
- 3 sites in Netherlands
- Volunteers
- 600 people
- Sponsor
- Maastricht University Medical Center
Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Frailty
Immune Aging and Advanced Therapy Outcomes in Older Adults With IBD
The goal of this observational study is to learn whether signs of immune aging and frailty can help predict the balance of benefits and risks of advanced therapies in adults aged 60 years or older with inflammatory bowel disease…
- Conditions
- Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Frailty, Immunosenescence
- Trial name
- NCT07828886
- Volunteers
- 300 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Crohn's Diseases
Effect of Intestinal Carriage of *Pilosibacter Rotomagensis* on Intestinal Inflammatory Activity
Crohn's disease is a chronic inflammatory condition that can affect the entire digestive tract. The terminal ileum is the segment most frequently involved, and approximately one-third of patients present with disease limited to…
- Trial name
- ProsPec (NCT07871383)
- Testing
- Microbiota suspension
- Where
- France
- Volunteers
- 116 people
- Sponsor
- University Hospital, Rouen
Enteric Hyperoxaluria
Efficacy and Safety of TRA16 Administered Orally in Patients With Enteric Hyperoxaluria (EH).
A Phase II, Multi-center, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of TRA16 Administered Orally in Patients with Enteric Hyperoxaluria (EH).
- Trial name
- NCT07871669
- Testing
- TRA16
- Volunteers
- 30 people
- Sponsor
- Wuhan Kangfude Urolithiasis Research Institute Co., Ltd.
Inflammatory Bowel Diseases, Crohn's
The Canadian Children Inflammatory Bowel Disease Network (CIDsCaNN)
The CIDsCaNN Network is being established with the major goals of identifying why IBD develops so commonly in children and adolescents living in Canada, and of determining the best treatment strategies for different types of IBD.
- Conditions
- Inflammatory Bowel Diseases, Crohn's, Ulcerative Colitis
- Trial name
- CIDsCaNN (NCT02308917)
- Where
- 12 sites in Canada
- Volunteers
- 2,400 people
- Sponsor
- The Hospital for Sick Children
Ulcerative Colitis, Healthy
Genome Analysis Across Populations in Inflammatory Bowel Disease
Objective: To use clinical, genetic and genome analysis to better understand and define the genetic and environmental factors that contribute to IBD within affected populations.
- Conditions
- Ulcerative Colitis, Healthy, Crohn Disease, Inflammatory Bowel Diseases
- Trial name
- NCT06042387
- Testing
- Blood or saliva sample collection
- Where
- Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Mount Sinai Hospital, Canada
Ulcerative Colitis, Crohn's Disease
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
The main aim of this study is to learn about medical problems (adverse events) if vedolizumab subcutaneously (SC) is given to a child or teenager with UC or CD for a long time.
- Trial name
- NCT06405087
- Testing
- Vedolizumab SC, No Intervention
- Where
- 47 sites in United States, Belgium and 12 more
- Volunteers
- 70 people
- Sponsor
- Takeda
Crohn Disease, Healthy
Reducing Fatigue With CoQ10 Supplementation in Patients With Crohn's Disease Study
This study includes an open label clinical trial comparing two doses of CoQ10 for 8 weeks to improve fatigue among patients with Crohn's disease and a prospective cohort study of healthy controls taking CoQ10 for 2 weeks.
- Trial name
- NCT06419335
- Testing
- CoQ10
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Inflammatory Bowel Disease (IBD), Crohn's Disease
Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
The goal of this observational study is to assess the feasibility and effectiveness of a remote monitoring digital health system on adherence, clinical outcomes, and healthcare utilization in patients with inflammatory bowel…
- Conditions
- Inflammatory Bowel Disease (IBD), Crohn's Disease, Ulcerative Colitis
- Trial name
- MONITOR (NCT06750731)
- Testing
- Tappt
- Where
- 6 sites in United States
- Volunteers
- 200 people
- Sponsor
- Mercy Medical Center
Crohn's Disease
A Study of CDPATH™ to Help Manage and Treat Crohn's Disease
CDPATH™ is a tool to help predict the potential for developing Crohn's disease related complications in certain adult participants within 3 years.
- Trial name
- COMPASS-CD (NCT04809363)
- Testing
- CDPATH™, Blood Draw
- Where
- 44 sites in United States
- Volunteers
- 241 people
- Sponsor
- Takeda
Irritable Bowel Syndrome, Inflammatory Bowel Diseases
A Personalized Approach to Abdominal Pain in Irritable Bowel Syndrome
Apart from its use to provide insight in IBS disease courses and in clinical research, ESM can provide patients with feedback about individual triggers of their symptoms, and thereby function as part of a personalized therapeutic…
- Conditions
- Irritable Bowel Syndrome, Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
- Trial name
- PERCEPTIvE (NCT05998577)
- Testing
- ESM and Traqq
- Where
- Netherlands
- Volunteers
- 120 people
- Sponsor
- Maastricht University Medical Center
Inflammatory Bowel Diseases, Crohn's Disease
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 3 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's…
- Trial name
- GARNET (NCT06226883)
- Testing
- MORF-057
- Where
- 225 sites in United States, Australia and 26 more
- Volunteers
- 385 people
- Sponsor
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Crohn Disease
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
The main purpose of this study is to see how the safety and efficacy of a farnesoid X receptor (FXR) agonist (LY4395089), given together with mirikizumab compares with mirikizumab (alone) in adults with moderately to severely…
- Trial name
- NCT07483099
- Testing
- LY4395089, Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC)
- Where
- 70 sites in United States, Belgium and 8 more
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Crohns Disease
A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the safety of Guselkumab in participants with Crohn's disease.
- Trial name
- NCT04397263
- Testing
- Guselkumab
- Where
- 25 sites in Japan
- Volunteers
- 38 people
- Sponsor
- Janssen Pharmaceutical K.K.